Palvella Therapeutics (NASDAQ:PVLA) Receives Consensus Rating of “Buy” from Analysts

Palvella Therapeutics (NASDAQ:PVLA) has been given a consensus recommendation of “Buy” by the six analysts that are currently covering the company, Marketbeat Ratings reports. Six research analysts have rated the stock with a buy rating. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $43.20.

Several analysts have weighed in on PVLA shares. Canaccord Genuity Group reaffirmed a “buy” rating and set a $39.00 price objective on shares of Palvella Therapeutics in a research note on Wednesday, February 26th. Jones Trading initiated coverage on Palvella Therapeutics in a research note on Tuesday. They issued a “buy” rating and a $45.00 target price for the company. Cantor Fitzgerald started coverage on shares of Palvella Therapeutics in a research report on Wednesday, December 18th. They set an “overweight” rating on the stock. HC Wainwright reiterated a “buy” rating and set a $38.00 target price on shares of Palvella Therapeutics in a research report on Tuesday, February 11th. Finally, Scotiabank initiated coverage on Palvella Therapeutics in a report on Friday, March 7th. They set a “sector outperform” rating and a $50.00 price objective on the stock.

Institutional Investors Weigh In On Palvella Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in PVLA. Citadel Advisors LLC acquired a new stake in Palvella Therapeutics in the 4th quarter valued at approximately $125,000. Toronto Dominion Bank bought a new position in shares of Palvella Therapeutics in the 4th quarter valued at about $159,000. Geode Capital Management LLC bought a new stake in Palvella Therapeutics in the fourth quarter valued at approximately $171,000. Cresset Asset Management LLC bought a new stake in shares of Palvella Therapeutics during the fourth quarter worth approximately $251,000. Finally, Renaissance Technologies LLC acquired a new position in shares of Palvella Therapeutics during the 4th quarter worth approximately $256,000. 40.11% of the stock is currently owned by institutional investors and hedge funds.

Palvella Therapeutics Trading Down 2.4 %

PVLA stock traded down $0.68 during trading on Tuesday, hitting $27.19. The company had a trading volume of 28,214 shares, compared to its average volume of 61,300. The stock has a market capitalization of $305.10 million, a P/E ratio of -2.25 and a beta of 0.54. The firm’s fifty day moving average is $19.08. Palvella Therapeutics has a fifty-two week low of $6.20 and a fifty-two week high of $29.27.

About Palvella Therapeutics

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.